SABS Share Price Performance
US$2.23
-0.37 (-14.23%)
Price US$2.23
Share PriceUS$2.23
SABS Community Narratives
There are no narratives available yet.
Recent SABS News & Updates
No updates
SAB Biotherapeutics, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -3.69
- Gross Margin
- -7,777.23%
- Net Profit Margin
- -9,071.77%
- Debt/Equity Ratio
- 0.6%
SAB Biotherapeutics, Inc. Competitors
About SABS
- Founded
- 2014
- Employees
- 63
- CEO
- WebsiteView website
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 11.4%
- 1 Year: 20.5%
- Year to Date: 5.9%
Over the last 7 days, the market has dropped 2.7%, driven by a loss of 2.4% in the Information Technology sector. As for the longer term, the market has actually risen by 20% in the last year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading